Regina R. Sarmanayeva

Regina R. Sarmanayeva

Auto-generated profile, based on publicly available information

Regina R. Sarmanayeva

P. A. Hertsen Moscow Oncology Research Institute – a branch of the National Medical Research Centre for Radiology of the Ministry of Health of Russia; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
GAG.R. Abuzarova
G.R. Abuzarova
VKVyacheslav Kosorukov
Vyacheslav Kosorukov
OGO.YU. Gamzeleva
O.YU. Gamzeleva
RSR.R. Sarmanaeva
R.R. Sarmanaeva
YBYu.V. Brazhnicova
Yu.V. Brazhnicova
Необходимость создания новых безопасных препаратов для адекватного контроля боли у онкологических пациентов очевидна. Одним из направлений является поиск селективных молекул, взаимодействующих с μ1-опиоидными рецепторами, лишенных многих побочных эффектов опиоидов. Такой препарат создан в России — это Тафалгин, при этом он не имеет зарубежных аналогов. ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить эффективность и безопасность анальгетика Тафалгина у онкологических пациентов с хроническим болевым синдромом (ХБС), подтвердить гипотезу о неменьшей эффективности Тафалгина в сравнении с морфином. МАТЕРИАЛ И МЕТОДЫ На базе 5 клинических центров проведено открытое сравнительное многоцентровое рандомизированное клиническое исследование III фазы по изучению эффективности и безопасности Тафалгина у онкологических пациентов с ХБС. Пациенты рандомизированы в две группы: 1-я группа (n=120) получала только Тафалгин подкожно; 2-я группа (n=59) — таблетки морфина 28 дней (период 1) и далее Тафалгин 28 дней (период 2). Первичной конечной точкой эффективности была частота сохранения ответа на обезболивающую терапию к 28-му дню. ХБС оценивали по цифровой рейтинговой шкале (NRS 0/10 баллов); по 5-балльной шкале Лайкерта для пациентов и врачей; по опроснику качества жизни SF-36. Анализ безопасности проводили на основании оценки частоты и выраженности нежелательных явлений (НЯ). РЕЗУЛЬТАТЫ Всего обследовано 179 пациентов (популяция ITT); завершили обследование 143 пациента (популяция PP). В 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню составила 98,97%, во 2-й группе — 100,00% (p=0,6783) для популяции РР. Для популяции ITT: в 1-й группе доля пациентов с сохранением ответа на обезболивающую терапию к 28-му дню была 84,17%, во 2-й группе — 88,14% (p=0,4787). Не выявлено случаев неэффективной терапии Тафалгином. Среднее значение NRS в популяция PP в начале терапии составило 0,42±0,48 и 0,30±0,47 балла в 1-й и 2-й группах (p=0,1250); к 28-му дню — 0,38±0,44 и 0,28±0,30 балла в этих группах (p=0,3472). В популяции ITT: NRS исходно составил 0,53±0,61 и 0,51±0,81 балла в 1-й и 2-й группах, (p=0,3519); к 28-му дню — 0,54±0,81 и 0,41±0,50 балла соответственно, (p=0,4536). После перевода пациентов с морфина на Тафалгин сохранился адекватный контроль боли через 56 и 84 дня терапии. На фоне приема Тафалгина определялась меньшая частота возникновения НЯ. ЗАКЛЮЧЕНИЕ Тафалгин оказывает выраженное обезболивающее действие, не уступающее морфину при лечении онкологического ХБС, имеет благоприятный профиль безопасности и меньшую частоту НЯ относительно морфина.

26 October 2021 in Annals of Critical Care
Verified
Journal Article
Open access
VPVera I. Potievskaya
Vera I. Potievskaya
FSF. M. Shvetskiy
F. M. Shvetskiy
DSD. V. Sidorov
D. V. Sidorov
MLM. V. Lozhkin
M. V. Lozhkin
MPMikhail Potievskiy
Mikhail Potievskiy
GAG. S. Alekseeva
G. S. Alekseeva
Introduction. The present study was designed to evaluate analgetic effect of xenon-oxygen mixture inhalations in oncological patients with abdominal tumors in postoperative period. Materials and methods. It was randomized blind placebo-controlled clinical trial, which was performed in 60 patients: 31 of them were in the main group and received xenon-oxygen mixture containing 25 ± 5 % xenon and other 29 were in the placebo group and received oxygen-air mixture. Results. According to the visual-analogical scale of pain, significant decreasing of the pain level was found in the main group after the inhalation and 30 minutes later in 90.3 % (p < 0.01) and 80.6 % of patients (p < 0.05) accordingly. The same result was found in the placebo group in 37.9 % of patients after oxygen-air mixture inhalation and 30 minutes later in 27.4 % of patients. The pain threshold measured with transcutaneal electroneurostimulation significantly increased in the xenon group after the inhalation (p < 0.01) and 30 minutes later (p < 0.05). In the placebo group no difference between the measurements was found. Conclusions. Xenon-oxygen mixture inhalation leads to the postoperative pain level reduction and increases the pain threshold in oncological patients.

25 November 2022 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
GAGusal R. Abuzarova
Gusal R. Abuzarova
RSRegina R. Sarmanayeva
Regina R. Sarmanayeva
GAGalina S. Alekseeva
Galina S. Alekseeva
YBYulia V. Brazhnicova
Yulia V. Brazhnicova
In the Russian Federation, tetrapeptide tyrosyl-D-arginyl-phenylalanyl-glycine amide (Tafalgin), a novel analgesic, selective agonist of 1-opioid receptors, was developed and approved in 2022. The article presents the first experience of the successful use of Tafalgin in treating chronic pain in a cancer patient with poor tolerance to traditional opioids (tramadol, tapentadol, morphine). At baseline, pain severity, according to the Neurological Rating Scale (NRS), was 57 points at rest and up to 9 points in motion out of the maximum 10. The combination of 400 mg/day of tramadol with gabapentin and a non-steroidal anti-inflammatory drug was ineffective; 400 mg/day of tapentadol in combination with gabapentin and a non-steroidal anti-inflammatory drug also was ineffective. Morphine tablets 60 mg/day were effective (NRS score of 23), but unrelenting nausea and vomiting were unmanageable and significantly reduced quality of life. Reducing the dose of oral morphine to 20 mg/day mitigated adverse events but reduced the effectiveness of pain relief (resting NRS score of 4 points). Tafalgin 4 mg subcutaneously BID, then TID reduced the pain severity to an average daily NRS score of 1.22 over the first 3 days of treatment with no adverse events. Sleep, appetite, and physical activity improved. The patient received Tafalgin for 84 days, and she gained 5 kg due to improved nutrition during that time. The drug is comparable in efficacy to morphine and is associated with fewer adverse events. A limitation to widespread use is the availability of a formulation for subcutaneous injection only.

23 June 2021 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
AKAndrei Kaprin
Andrei Kaprin
GAG. R. Abuzarova
G. R. Abuzarova
DNDiana Nevzorova
Diana Nevzorova
GAG. S. Alekseeva
G. S. Alekseeva
EGE. V. Gameeva
E. V. Gameeva
SKS. V. Kuznetcov
S. V. Kuznetcov
In this article we performed publication analysis devoted to pain medicine in oncology during anticancer therapy and in palliative setting. Until recently, the main WHO guidelines for pain management in oncology were the recommendations of 1996, which included only pain relievers, as well as adjuvant and symptomatic drugs, which were applied according to the WHO analgesic ladder. These recommendations were based on the collective expert opinion of leading clinicians and scientists. The new WHO clinical guidelines were published in 2019. They are based on the principles of evidence-based medicine, including modern concepts of the etiology and pathogenesis of tumor pain syndrome. This recommendations contain sections on the analgesic efficacy of radiation therapy and antitumor drug therapy. The new WHO recommendations have not yet been published in Russian and are not sufficiently available for a wide range of oncologists and palliative specialists in our country. The purpose of this publication is to present within one volume a concise but complete and comprehensible discussion of the latest trends in pain therapy in oncology, published by WHO experts.

16 December 2020 in Head and Neck Tumors (HNT)
Verified
Journal Article
Open access
PDF file
AGA. R. Gevorkov
A. R. Gevorkov
ABA. V. Boyko
A. V. Boyko
LBLarisa Bolotina
Larisa Bolotina
SSS. V. Shashkov
S. V. Shashkov
GAG. R. Abuzarova
G. R. Abuzarova
RSR. R. Sarmanaeva
R. R. Sarmanaeva
The study objective is to improve quality of life in patients with oropharyngeal squamous-cell carcinoma during chemo/bioradiation therapy and at early stages after its completion which allows to perform the full extent of radiation within optimal treatment period.Materials and methods. A retrospective analysis of data on 196 patients who underwent chemoradiation therapy between 2005 and 2016 was performed. The results were used to develop and implement a program of support for chemo/bioradiotherapy. The program was characterized by: 1. use of Russian hydrogel materials for local delivery of antibiotics and wound-healing, anesthetizing, anti-inflammatory medications; 2. new regimens of pain relief with differentiated pathogenetic approach and use of modern transdermal long-acting forms; 3. nutritional support at every treatment stage; 4. assurance of compliancy. To evaluate the program, prospective randomized controlled study was performed between January of 2017 and March of 2019 including 60 patients.Results. Mucositis and dermatitis severity and changes in physical state associated with them, progression and duration of radiation did not significantly differ in the two groups. Use of the support program allowed to control adverse effects and to perform chemoradiotherapy to the full extent, at optimal time and with satisfactory quality of life.Conclusion. The program of support of chemo/bioradiotherapy in combination with psychological support is effective both form the point of view of optimization of treatment and rehabilitation times and from the point of view of maintenance of high quality of life in patients.

16 November 2020 in Annals of Critical Care
Verified
Journal Article
Open access
GAG. R. Abuzarova
G. R. Abuzarova
VKV. E. Khoronenko
V. E. Khoronenko
RSRegina R. Sarmanayeva
Regina R. Sarmanayeva
SKS. V. Kuznetcov
S. V. Kuznetcov
Objectives. To evaluate safety and efficacy of administering a 50/50 mixture of xenon and oxygen gases to patients with moderate-to-severe cancer pain. Materials and methods. The study included 131 patients with moderate-to-severe cancer pain, who had been randomized into two groups: patients to receive inhalation of a mixture of xenon and oxygen in a volume ratio of 50/50, and those to receive inhalation of a mixture of oxygen and air. Efficacy was evaluated based on the following measurements: intensity of pain by NRS 30 minutes after each procedure; at the end of treatment; 2 weeks after treatment. Safety was assessed by dynamics of hemodynamic and laboratory parameters; incidence of adverse events in each group. Results. The study results showed that the median decrease in pain intensity measured by NRS 30 minutes after inhalation of xenon-oxygen mixture was –19.00 (–24.50 to 13.25) against –4.00 (–6.00 to 2.00) in the placebo group: the results attested to statistically significant differences (p < 0.001) and a superior analgesic efficacy of xenon-oxygen mixture over placebo. Following the course of treatment, a significant NRS-measured decrease from 50.00 (40.00–60.00) to 30.00 (20.00–41.25) mm was registered in the active treatment group compared to an unverifiable decrease in NRS from 60.00 (35,00–70.00) to 55.0 (35.00–60.00) mm in the placebo group. The course of xenon inhalations made it possible to significantly reduce average daily doses of tramadol from 210.9 ± 31.3 mg to 150.1 ± 28.3, and also significantly reduce NSAID intake. AEs (n = 8) were observed only in 7 patients in the group receiving xenon therapy. Аll AEs were mild. Conclusions. Xenon-oxygen mixture was safe and performed better than placebo for analgesia in cancer pain treatment.